CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 641 - 650 of 730
Study Number Lead Group Study Title CIRB Study Status
9853 ETCTN A Phase 1 Study of AZD1775 in Combination with Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients with Acute Myeloid Leukemia Adult CIRB - Early Phase Emphasis Available to Open
9846 ETCTN Patient-Derived Models Tissue Procurement Protocol For The National Cancer Institute (NCI) Adult CIRB - Early Phase Emphasis Available to Open
9844 ETCTN A Phase 1 Study Evaluating Safety; Tolerability; and Preliminary Antitumor Activity of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors Adult CIRB - Early Phase Emphasis Available to Open
9837 ETCTN Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors; with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin Adult CIRB - Early Phase Emphasis Available to Open
9825 ETCTN A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer Adult CIRB - Early Phase Emphasis Available to Open
9824 ETCTN A Phase 1 Study of alisertib (MLN8237) in combination with mFOLFOX in gastrointestinal tumors Adult CIRB - Early Phase Emphasis Available to Open
9782 ETCTN A Phase 1 Study of BMN 673 in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors Adult CIRB - Early Phase Emphasis Available to Open
9775 ETCTN A Phase 2 Study of MLN0128 in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL) Adult CIRB - Early Phase Emphasis Available to Open
9767 ETCTN An Open Label; Multicenter; Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor; MLN0128 (TAK-228); in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or a TSC2 mutation Adult CIRB - Early Phase Emphasis Available to Open
9742 ETCTN Multicenter Phase II Study of Nivolumab in Previously Treated Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma Adult CIRB - Early Phase Emphasis Available to Open
Displaying 641 - 650 of 730